Business Context and Reporting Period
Company: Coca-Cola Europacific Partners Plc (CCEP)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 12, 2025
Context: This filing is a shareholder letter providing additional context regarding specific resolutions for the Annual General Meeting (AGM) scheduled for May 22, 2025. The letter addresses divergent recommendations from proxy advisory firms (Glass Lewis, ISS, and IVIS) concerning a waiver of mandatory offer provisions and director re-elections.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and shareholder voting matters.
- Share Buyback Programme: Announced on February 14, 2025, with an aggregate value of up to €1 billion.
- Buyback Period: Expected to run through February 2026, subject to market conditions.
- Major Shareholder (Olive): Currently holds approximately 36.1% of issued share capital.
- Projected Ownership Post-Buyback: If the full €1 billion programme is executed, Olive's shareholding could increase to approximately 40.1%.
Material Changes and Governance Issues
The filing highlights significant governance debates regarding three specific resolutions:
- Resolution 24 (Rule 9 Waiver): Seeks a waiver under Rule 9 of the UK Takeover Code to allow share repurchases without triggering a mandatory general offer from Olive (who holds >30%).
- Proxy Advisory Stance: Glass Lewis recommends "FOR"; ISS recommends "AGAINST" (citing outdated policy); IVIS assigns a "RED" designation but leaves the decision to shareholder judgment.
- Company Position: Management argues the waiver is necessary for the buyback programme, which is supported by cash flows and will not create excessive leverage. They assert ISS's opposition is based on a rigid policy not updated since 2020.
- Resolutions 5 and 8 (Director Re-elections): Concern the re-election of Manolo Arroyo and José Ignacio Comenge.
- Proxy Advisory Stance: ISS recommends "AGAINST" due to concerns that these directors are not independent and sit on the Remuneration Committee. Glass Lewis recommends "FOR".
- Company Position: The Board maintains the Remuneration Committee complies with terms of reference (majority of Independent Non-executive Directors) and that these directors have no conflicts of interest.
Guidance, Outlook, and Risks
Management Commentary:
- Shareholder Intent: Olive has confirmed it has no intention of changing its approach to CCEP or seeking a change in the general nature of the business, regardless of any increase in shareholding resulting from the buyback.
- Control Safeguards: Even if the buyback is fully executed, Olive's voting rights will not exceed 50%, and any further increase would trigger Rule 9 provisions.
- Financial Prudence: Management asserts the buyback is a prudent use of cash resources supported by underlying business cash flows.
Risks and Contingencies:
- Voting Risk: Divergent proxy advice (specifically from ISS and IVIS) may influence shareholder voting outcomes on critical governance resolutions.
- Regulatory Risk: The waiver of Rule 9 is contingent upon Independent Shareholder approval.
Key Facts for Investor Verification
- Verify the current share price to assess the actual percentage of share capital Olive would acquire if the €1 billion buyback is fully executed (currently estimated at <10% of total capital).
- Confirm the composition of the Remuneration Committee to ensure it maintains a majority of Independent Non-executive Directors as claimed by management.
- Review Olive's formal statement regarding its long-term intentions for CCEP to validate the claim that "creeping control" is not a risk.
- Monitor the AGM voting results on May 22, 2025, specifically for Resolutions 5, 8, and 24, as these are prerequisites for the share buyback programme.